Source: https://www.federalregister.gov/documents/2014/02/27/2014-01959/new-animal-drugs-bambermycins-clopidol-ivermectin-penicillin-g-procaine-and-dihydrostreptomycin
Timestamp: 2017-08-22 09:38:29
Document Index: 457478208

Matched Legal Cases: ['arts 520', '§\u200925', '§\u200925', '§\u200925', '§\u200925', 'arts 510', '§\u2009510', '§\u2009520', '§\u2009520', '§\u2009522', '§\u2009510', 'art 526', '§\u2009526', '§\u2009526', 'art 529', '§\u2009529', '§\u2009556', '§\u2009556', 'art 558', '§\u2009558', '§\u2009558']

Federal Register :: New Animal Drugs; Bambermycins; Clopidol; Ivermectin; Penicillin G Procaine and Dihydrostreptomycin Sulfate; Progesterone; Robenicoxib; Sulfadimethoxine; Change of Sponsor; Change of Sponsor's Address
New Animal Drugs; Bambermycins; Clopidol; Ivermectin; Penicillin G Procaine and Dihydrostreptomycin Sulfate; Progesterone; Robenicoxib; Sulfadimethoxine; Change of Sponsor; Change of Sponsor's Address
10963-10965 (3 pages)
21 CFR Parts 520, 522, 526, and 529
https://www.federalregister.gov/d/2014-01959 https://www.federalregister.gov/d/2014-01959
Start Preamble Start Printed Page 10963
The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval actions for new animal drug applications (NADAs) and abbreviated new animal drug applications (ANADAs) during December 2013. FDA is also informing the public of the availability of summaries of the basis of approval and of environmental review documents, where applicable. The animal drug regulations are also being amended to reflect a change of sponsorship of an NADA and a change to a sponsor's address.
FDA is amending the animal drug regulations to reflect approval actions for NADAs and ANADAs during December 2013, as listed in table 1. In addition, FDA is informing the public of the availability, where applicable, of documentation of environmental review required under the National Environmental Policy Act (NEPA) and, for actions requiring review of safety or effectiveness data, summaries of the basis of approval (FOI Summaries) under the Freedom of Information Act (FOIA). These public documents may be seen in the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain these documents at the Center for Veterinary Medicine FOIA Electronic Reading Room: http://www.fda.gov/​AboutFDA/​CentersOffices/​OfficeofFoods/​CVM/​CVMFOIAElectronicReadingRoom/​default.htm.
In addition, West Agro, Inc., 11100 North Congress Ave., Kansas City, MO 64153 has informed FDA that it has transferred ownership of, and all rights and interest in, NADA 055-028 for QUARTERMASTER (penicillin G procaine and dihydrostreptomycin sulfate) Dry Cow Treatment to HQ Specialty Pharma Corp., 120 Rte. 17 North, Suite 130, Paramus, NJ 07652. Following this change of sponsorship, West Agro, Inc., is no longer a sponsor of an approved NADA, and HQ Specialty Pharma Corp. is now the sponsor of an approved NADA. Also, Putney, Inc., 400 Congress St., Suite 200, Portland, ME 04101 has informed FDA of a change of address to One Monument Sq., Suite 400, Portland, ME 04101. Accordingly, the Agency is amending the regulations to reflect this change of sponsorship and change of sponsor's address.
Table 1—Original and Supplemental NADAs and ANADAs Approved During December 2013
141-419 Huvepharma AD, 5th Floor, 3A Nikolay Haytov St., 1113 Sophia, Bulgaria COYDEN 25 (clopidol) plus FLAVOMYCIN (bambermycins) Type A medicated articles Original approval as an aid in prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati; and for increased rate of weight gain and improved feed efficiency in broiler chickens 558.95, 558.175 Yes CE.1 2
200-523 Cross Vetpharm Group Ltd., Broomhill Rd., Tallaght, Dublin 24, Ireland SULFAMED (sulfadimethoxine) 40% Injectable Solution Original approval as a generic copy of NADA 041-245 522.2220 Yes CE.1 3
200-564 Merial Ltd., 3239 Satellite Blvd., Bldg. 500, Duluth, GA 30096-4640 Ivermectin Paste 1.87% Original approval as a generic copy of NADA 134-314 4 N/A Yes CE.1 3
141-200 Zoetis Inc., 333 Portage St., Kalamazoo, MI 49007 EAZI-BREED CIDR (progesterone intravaginal insert) Cattle Insert Supplemental approval for induction of estrous cycles in anestrous lactating dairy cattle 529.1940 Yes EA/FONSI.5
141-320 Novartis Animal Health US, Inc., 3200 Northline Ave., Suite 300, Greensboro, NC 27408 ONSIOR (robenacoxib) Tablets Supplemental approval lowering age at treatment from 6 months to 4 months 520.2075 Yes CE.1 6
200-341 Sparhawk Laboratories, Inc., 12340 Santa Fe Trail Dr., Lenexa, KS 66215 SPARMECTIN-E (ivermectin) Liquid Supplemental approval adding pathogens off exclusivity to labeling 520.1195 Yes CE.1 3
1 The Agency has determined under § 25.33 (21 CFR 25.33) that this action is categorically excluded (CE) from the requirement to submit an environmental assessment (EA) or an environmental impact statement because it is of a type that does not individually or cumulatively have a significant effect on the human environment.
2 CE granted under § 25.33(a)(2).
3 CE granted under § 25.33(a)(1).
4 21 CFR 520.1192 already contains a drug labeler code entry for this sponsor.
5 The Agency has carefully considered an EA of the potential environmental impact of this action and has made a finding of no significant impact (FONSI).
6 CE granted under § 25.33(d)(1).
Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR parts 510, 520, 522, 526, 529, and 558 are amended as follows:
2. In § 510.600, in the table in paragraph (c)(1), alphabetically add an entry for “HQ Specialty Pharma Corp.”, revise the entry for “Putney, Inc.”, and remove the entry for “West Agro, Inc.”; and in the table in paragraph (c)(2), revise the entry for “026637”, remove the entry for “033392”, and numerically add an entry for “042791” to read as follows:
HQ Specialty Pharma Corp., 120 Rte. 17 North, Suite 130, Paramus, NJ 07652 042791
Putney, Inc., One Monument Sq., Suite 400, Portland, ME 04101 026637
026637 Putney, Inc., One Monument Sq., Suite 400, Portland, ME 04101.
042791 HQ Specialty Pharma Corp., 120 Rte. 17 North, Suite 130, Paramus, NJ 07652.
4. In § 520.1195, revise paragraphs (b)(1) and (b)(2) to read as follows:
(1) Nos. 000859, 050604, 054925, and 058005 for use of product described in paragraph (a)(1) of this section as in paragraphs (e)(1)(i), (e)(1)(ii)(A), and (e)(1)(iii) of this section.
(2) No. 058829 for use of product described in paragraph (a)(1) of this section as in paragraphs (e)(1)(i), (e)(1)(ii)(B), and (e)(1)(iii) of this section.
5. In § 520.2075, in paragraph (c)(2), remove “at least 6 months of age” and in its place add “at least 4 months of age”.
7. In § 522.2220, revise paragraphs (a)(1), (a)(2), and (a)(3)(iii) to read as follows:
(a)(1) Specifications. Each milliliter of solution contains 400 milligrams (mg) sulfadimethoxine.
(2) Sponsors. See sponsor numbers in § 510.600(c) of this chapter for conditions of use as in paragraph (a)(3) of this section:
(i) No. 054771 for use as in paragraph (a)(3) of this section.
(ii) Nos. 000859, 057561, and 061623 for conditions of use as in paragraph (a)(3)(iii) of this section.
(iii) Cattle—(a) Amount. Administer an initial dose of 25 mg per pound of body weight by intravenous injection followed by 12.5 mg per pound of body weight every 24 hours until the animal is asymptomatic for 48 hours.
(b) Indications for use. For the treatment of bovine respiratory disease complex (shipping fever complex) and bacterial pneumonia associated with Pasteurella spp. sensitive to sulfadimethoxine; necrotic pododermatitis (foot rot) and calf diphtheria caused by Fusobacterium necrophorum sensitive to sulfadimethoxine.Start Printed Page 10965
(c) Limitations. Milk taken from animals during treatment and for 60 hours (5 milkings) after the latest treatment must not be used for food. Do not administer within 5 days of slaughter. A withdrawal period has not been established for this product in preruminating calves. Do not use in calves to be processed for veal.
8. The authority citation for 21 CFR part 526 continues to read as follows:
§ 526.1696c
9. In paragraph (b) of § 526.1696c, remove “033392” and in its place add “042791”.
10. The authority citation for 21 CFR part 529 continues to read as follows:
11. In § 529.1940, in paragraphs (b) and (e)(1)(iii), remove “000009” and in its place add “054771”; in paragraph (c), remove “§ 556.540(a)” and in its place add “§ 556.540”; and add paragraph (e)(1)(ii)(D) to read as follows:
12. The authority citation for 21 CFR part 558 continues to read as follows:
13. In paragraph (d)(5) of § 558.95, redesignate paragraphs (d)(5)(iii) through (d)(5)(x) as paragraphs (d)(5)(iv) through (d)(5)(xi); and add new paragraph (d)(5)(iii) to read as follows:
14. In § 558.175:
a. Redesignate paragraph (d)(9) as paragraph (d)(11).
b. Redesignate paragraphs (d)(5) through (d)(8) as paragraphs (d)(6) through (d)(9).
c. Add new paragraphs (d)(5) and (d)(10).
(5) 113.5 Bambermycins 1 to 2 Broiler chickens: As an aid in prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati; and for increased rate of weight gain and improved feed efficiency Feed continuously as the sole ration. Do not feed to chickens over 16 weeks of age 016592
(10) 227 Bambermycins 1 to 2 Broiler chickens: As an aid in prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, and E. mivati; and for increased rate of weight gain and improved feed efficiency Feed continuously as sole ration until 5 days before slaughter. Withdraw 5 days before slaughter or feed 113.5 g/ton clopidol and 1 to 2 g/ton bambermycins during those 5 days before slaughter. Do not feed to chickens over 16 weeks of age 016592
[FR Doc. 2014-01959 Filed 2-26-14; 8:45 am]